Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 4/2020

01-12-2020 | Degenerative Disease

Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases

Authors: Andreea Iulia Socaciu, Răzvan Ionuţ, Mihai Adrian Socaciu, Andreea Petra Ungur, Maria Bârsan, Angelica Chiorean, Carmen Socaciu, Armand Gabriel Râjnoveanu

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2020

Login to get access

Abstract

The last four decades, we assist to an increasing scientific interest on melatonin, a circadian hormone, a metabolic regulator which influences not only plants’ metabolism and their defense against pathogens but mostly the animals and humans’ metabolic pathways, their response to circadian disruption, stress and burnout syndrome. In humans, as a hormonal regulator, produced in the pineal grand as well in mitochondria, melatonin is involved in different, complex intracellular signaling pathways, with antioxidant and immune stimulating effects, proving to act as a circadian synchronizer, as a preventive and therapeutic agent in many degenerative diseases, and especially in hormone-dependent cancers. Preclinical or clinical studies showed recently the mechanisms involved in regulating the cellular activity, its role in aging and circadian disturbances and impact on degenerative diseases. Melatonin proved to have an anti-inflammatory, antiapoptotic and powerful antioxidant effect by subtle mechanisms in mitochondrial metabolic pathways. This overview includes recent and relevant literature data related to the impact of endogenous and exogeneous melatonin on the prevention of cancer progression and treatment of various degenerative diseases. Metabolomics, an emerging new omics’ technology, based on high performance liquid chromatography coupled with mass spectrometry is presented as an encouraging technique to fingerprint and realize a precise evaluation and monitoring of the turnover of melatonin and its metabolites in different pathological circumstances.
Literature
1.
Lynch HJ, Wurtman RJ, Moskowitz MA, Archer MC, Ho MH. Daily rhythm in human urinary melatonin. Science. 1975;187(4172):169–71.PubMed
2.
Lewis A. Melatonin and the biological clock. McGraw-Hill 1999. ISBN 978-0-87983-734-1.
3.
Salehi B, Sharopov F, Tsouh Fokou PV, Kobylinska A, de Jonge L, Tadio K, Sharifi-rad J, Posmyk MM, Martorell M, Martins N, Iriti M. Melatonin in medicinal and food plants: occurrence, bioavailability, and health potential for humans. Cells. 2019;8(7):681–98.PubMedCentral
4.
Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res. 2013;54:127–38.PubMed
5.
Hardeland R. Melatonin in plants and other phototrophs: advances and gaps concerning the diversity of functions. J Exp Botany. 2015;66:627–46.
6.
Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, Hara M, Reiter RJ. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int. 1995;35:627–34.
7.
Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Rev. 1991;12:151–80.
8.
Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B. Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas. Cell Mol Life Sci. 2017;74:3863–81.PubMed
9.
Zhao D, Yu Y, Shen Y, et al. Melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol (Lausanne). 2019;10:249.
10.
Tan DX, Hardeland R, Manchester LC, Korkmaz A, Ma S, Rosales-Corral S, Reiter RJ. Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science. J Exp Botany. 2012;63:577–97.
11.
Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ. Phytomelatonin: a review. J Exp Botany. 2009;60:57–69.
12.
Nawaz MA, Huang Y, Bie Z, Ahmed W, Russel J, Reiter RJ, Niu M, Hameed S. Melatonin: current status and future perspectives in plant science. Front Plant Sci. 2016;6:1230–41.PubMedPubMedCentral
13.
Reiter RJ, Tan DX, Zhou Z, Cruz MH, Fuentes-Broto L, Galano A. Phytomelatonin: assisting plants to survive and thrive. Molecules. 2015;20:7396–437.PubMedPubMedCentral
14.
15.
Arnao MB, Hernández-Ruiz J. Functions of melatonin in plants: a review. J Pineal Res. 2015;59:133–50.PubMed
16.
Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci. 2005;26:412–9.PubMed
17.
Zhu Y, Gao H, Lu MX, Hao CY, Pu ZQ, Guo MJ, Hou DR, Chen LY, Huang X. Melatonin-nitric oxide crosstalk and their roles in the redox network in plants. Int J Mol Sci. 2019;20:6200.PubMedCentral
18.
Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28–42.PubMed
19.
Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27:119–30.PubMed
20.
Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253–78.PubMed
21.
Illnerova H, Buresova M, Presl J. Melatonin rhythm in human milk. J Clin Endocrinol Metab. 1993;77:838–41.PubMed
22.
Sae-Teaw M, Johns J, Johns NP, Subongkot S. Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers. J Pineal Res. 2013;55:58–64.PubMed
23.
Yilmaz C, Gokmen V. Neuroactive compounds in foods: occurrence, mechanism and potential health effects. Food Res Int. 2020;128:108744.PubMed
24.
Pereira N, Naufel MF, Ribeiro EB, Tufik S, Hachul H. Influence of dietary sources of melatonin on sleep quality: A review. J Food Sci. 2020;85:5–13.PubMed
25.
Hardeland R. Melatonin, hormone of darkness and more – occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci. 2008;65:2001–18.PubMed
26.
Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175:3190–9.PubMedPubMedCentral
27.
Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A. A review of melatonin, its receptors and drugs. Eurasian J Med. 2016;48:135–41.PubMedPubMedCentral
28.
Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, Barlow-Walden LR. Melatonin, a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci. 1994;738:419–20.PubMed
29.
Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci. 1994;55:271–6.
30.
Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, Vriend J, Tan DX, Reiter RJ. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403–19.PubMed
31.
Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res. 2008;45:235–46.PubMed
32.
Reiter RJ, Paredes SD, Korkmaz A, Jou MJ, Tan DX. Melatonin combats molecular terrorism at the mitochondrial level. Interdisc Toxicol. 2008;1:137–49.
33.
Sharafati-Chaleshtori R, Shirzad H, Rafieian-Kopaei M, Soltani A. Melatonin and human mitochondrial diseases. J Res Med Sci. 2017;22:2–10.PubMedPubMedCentral
34.
Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 2009;44:175–200.PubMed
35.
Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15:434–43.PubMedPubMedCentral
36.
Shirazi A, Ghobadi G, Ghazi-Khansari M. A radiobiological review on melatonin: a novel radioprotector. J Rad Res. 2007;48:263–72.
37.
Meltz ML, Reiter RJ, Herman TS, Kumar KS. Melatonin and protection from whole-body irradiation: survival studies in mice. Mutation Res. 1999;425:21–7.PubMed
38.
Reiter RJ, Herman TS, Meltz ML. Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutation Res. 1996;371:221–8.PubMed
39.
Reiter RJ, Herman TS, Meltz ML. Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes. Mutation Res. 1998;397:203–8.PubMed
40.
Schomerus C, Korf HW. Mechanisms regulating melatonin synthesis in the mammalian pineal organ. Ann N Y Acad Sci. 2005;1057:372–83.PubMed
41.
Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHA review 20. Br J Pharmacol. 2016;173:2702–25.PubMedPubMedCentral
42.
Tarocco A, Caroccia N, Morciano G, Wieckowski MR, Ancora G, Garani G, Pinton P. Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care. Cell Death Dis. 2019;10:317–26.PubMedPubMedCentral
43.
Liu L, Labani N, Cecon E, Jockers R. Melatonin target proteins: too many or not enough? Front Endocrinol. 2019;10:791.
44.
Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189–200.PubMed
45.
Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernández-Montesinos R, Guerrero JM, Pozo D. The modulatory role of melatonin on immune responsiveness. Curr Opinion Invest Drugs. 2006;7:423–31.
46.
Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs. 2001;10:467–76.PubMed
47.
Armstrong SM, Redman JR. Melatonin: a chronobiotic with anti-aging properties? Med Hypotheses. 1991;34:300–9.PubMed
48.
Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experintia. 1993;49:654–64.
49.
Kayumov L, Casper RF, Hawa RJ, Perelman B, Chung SA, Sokalsk S, Shapiro CM. Blocking low-wavelength light prevents nocturnal melatonin suppression with no adverse effect on performance during simulated shift work. J Clin Endocrinol Metab. 2005;90:2755–61.PubMed
50.
Hardeland R. Melatonin in aging and disease:multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012;3:194–225.PubMed
51.
Hardeland R, Madrid JA, Tan DX, Reiter RJ. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res. 2012;52:139–66.PubMed
52.
Abbott SM, Malkani RG, Zee PC. Circadian disruption and human health: A bidirectional relationship. Eur J Neurosci. 2020;51:567–83.PubMed
53.
Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ. Management of insomnia disorder. AHRQ Comparative Effectiveness Reviews. No. 159 2015.
54.
Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders (PDF). Sleep Med Reviews. 2017;34:10–22.
55.
Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis (PDF). Arch Disease Childhood. 2018;103:1155–62.
56.
Matheson E, Hainer BL. Insomnia: pharmacologic therapy. Am Fam Physician. 2017;96:29–35.PubMed
57.
Liira J, Verbeek JH, Costa G, Driscoll TR, Sallinen M, Isotalo LK, Ruotsalainen JH. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database Syst Rev. 2014;8:CD009776.
58.
Besag FMC, Vasey MJ, Lao KSJ, Wong ICK. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: A systematic review. CNS Drugs. 2019;33:1167–86.PubMed
59.
Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klasen TP, Baker B. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. Br Med J. 2006;332:385–93.
60.
Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disorders. 2006;36:741–52.
61.
Jonsdottir IH, Dahlman AS. Endocrine and immunological aspects of burnout: a narrative review. Eur J Endocrinol. 2019;180:R147–58.PubMed
62.
Bendz LM, Scates AC. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacotherapy. 2010;44:185–91.
63.
Valdés-Tovar M, Estrada-Reyes R, Solís-Chagoyán H, Argueta J, Dorantes-Barrón AM, Quero-Chávez D, Cruz-Garduno R, Cercos MG, Trueta C, Oikawa-Sala J, Dubocovich ML, Benitez-King G. Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression. Br J Pharmacol. 2018;175:3200–8.PubMedPubMedCentral
64.
Bonnefont-Rousselot D, Collin F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology. 2010;278:55–67.PubMed
65.
Reiter RJ, Tan DX, Korkmaz A, Erren TC, Piekarski C, Tamura H, Manchester LC. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncol. 2007;13:303–28.
66.
Chuffa L, Seiva F, Cucielo M, Silveira H, Reiter RJ, Lupi LA. Clock genes and the role of melatonin in cancer cells: an overview. Melatonin Res. 2019;2:133–57.
67.
Tan D-X. Reiter RJ mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells. Melatonin Res. 2019;2:44–66.
68.
Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K. Melatonin, a full service anticancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci. 2017;18:4.
69.
Reiter RJ, Sharma R, Ma Q, Rorsales-Corral S, Chuffa LGD. Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis. Cell Mol Life Sci. 2020:1–12.
70.
Ren W, Liu G, Chen S, Yin J, Wang J, Tan B, Wu G, Bazer FW, Peng Y, Tiejun L. Melatonin signaling in T cells: functions and applications. J Pineal Res. 2017;62:e12394.
71.
Liu Z, Yu K, Zheng J, Lin H, Zhao Q, Zhang X, Feng W, Wang L, Xu J, Xie D, Zuo Z-X, Liu Z-X, Zheng Q. Dysregulation, functional implications, and prognostic ability of the circadian clock across cancers. Cancer Med. 2019;8:1710–20.PubMedPubMedCentral
72.
Mortezaee K, Potes Y, Mirtavoos-Mahyari H, Motevaseli E, Shabeeb D, Musa AE, Najafi M, Farhood B. Boosting immune system against cancer by melatonin: A mechanistic viewpoint. Life Sci. 2019;238:116960.PubMed
73.
Boga JA, Caballero B, Potes Y, Perez-Martinez Z, Reiter RJ, Vega-Naredo I, Coto-Montes A. Therapeutic potential of melatonin related to its role as an autophagy regulator: A review. J Pineal Res. 2019;66:e12534.PubMed
74.
Giudice A, Crispo A, Grimaldi M, et al. The effect of light exposure at night (LAN) on carcinogenesis via decreased nocturnal melatonin synthesis. Molecules. 2018;23:E1308.PubMed
75.
Garaulet M, Qian J, Florez JC, Arendt J, Saxena R, Scheer FAJL. Melatonin effects on glucose metabolism: time to unlock the controversy. Trends Endocrinol Metab. 2020;31(3):192–204.PubMedPubMedCentral
76.
Tamtaji OR, Reiter RJ, Alipoor R, Dadgostar E, Kouchaki E, Asemi Z. Melatonin and Parkinson disease: current status and future perspectives for molecular mechanisms. Cell Mol Neurobiol. 2020;40:15–23.PubMed
77.
Shukla M, Chinchalongporn V, Govitrapong P, Reiter RJ. The role of melatonin in targeting cell signaling pathways in neurodegeneration. Ann N Y Acad Sci. 2019;1443:75–96.PubMed
78.
Zhang TW, Li ZF, Dong J, Jiang LB. The circadian rhythm in intervertebral disc degeneration: an autophagy connection. Exp Mol Med. 2020;52:31–40.PubMedPubMedCentral
79.
Ma Q, Reiter RJ, Chen YD. Role of melatonin in controlling angiogenesis under physiological and pathological conditions. Angiogenesis. 2020;23:91–104.PubMed
80.
Bartsch C, Bartsch H, Fluchter SH, Lippert TH. Depleted pineal melatonin production in primary breast and prostate cancer is connected with circadian disturbances: possible role of melatonin for synchronization of circadian rhythmicity. In: Touitou Y, Arendt J, Pevet P, editors. Melatonin and the pineal gland - from basic science to clinical application. Elsevier: New York; 1993. p. 311–6.
81.
Kos-Kudla B, Ostrowska Z, Kozlowski A, Marek BM, Ciesielska-Kopacz N, Kudla M, Kajdaniuk D, Strzelczyk J, Staszewicz P. Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuroendocrinol Lett. 2002;23:239–42.PubMed
82.
83.
Gil-Martin E, Egea J, Reiter RJ, Romero A. The emergence of melatonin in oncology: focus on colorectal cancer. Med Res Rev. 2019;39:2239–85.PubMed
84.
Aghazadeh-Attari M, Mohammadzadeh M, Mostavafi S, Mihanfar A, Ghazizadeh S, Sadighparvar S, Gholamzadeh S, Majidinia M, Yousefi B. Melatonin: an important anticancer agent in colorectal cancer. J Cell Physiol. 2020;235:804–17.
85.
Karasek M, Carillo-Vico A, Guerrero JM, Winczyk K, Pawlikowsky M. Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transposable murine Colon 38 cancer. Neuroendocrinol Lett. 2002;23:55–60.PubMed
86.
87.
88.
Mojaverrostami S, Asghari N, Khamisabadi M, Khoei HH. The role of melatonin in polycystic ovary syndrome: A review. Int J Reprod Biomed. 2019;17:865–82.PubMedPubMedCentral
89.
Rimler A, Lupowitz Z, Zisapel N. Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells. Neuroendocrinol Lett. 2002;23:45–9.PubMed
90.
Kubo T, Ozasa K, Mikami E, Wakai K, Fujino Y, Watanabe Y, Miki T, Nakao M, Hayashi K, Suzuki K, Mori M, Washio M, Sakauchi F, Ito Y, Yoshimura T, Tamakoshi A. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006;164:549–55.PubMed
91.
Shafabakhsh R, Reiter RJ, Mirzaei H, Teymoordash SN, Asemi Z. Melatonin: A new inhibitor agent for cervical cancer treatment. J Cell Physiol. 2019;234:21670–82.PubMed
92.
Kerenyi NA, Pandula E, Feuera G. Why the incidence of cancer is increasing: the role of ‘light pollution’. Med Hypotheses. 1990;33:75–8.PubMed
93.
Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V. On behalf of the WHO International Agency for Research on Cancer monograph working group, carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8:1065–6.PubMed
94.
Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther. 2009;8:337–46.PubMed
95.
Sanchez-Barcelo E, Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005;38:217–22.PubMed
96.
Shiu SY. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res. 2007;45:1–9.
97.
Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine. 2005;27:179–88.PubMed
98.
Blask DE, Sauer LA, Daunchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implication for circadian-based cancer therapy. Curr Top Med Chem. 2002;2:113–32.PubMed
99.
Korkmaz A, Sanchez-Barcelo EJ, Tan DX, Reiter RJ. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res Treat. 2009;115:13–27.PubMed
100.
Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR, Pozo D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell live both in vivo and in vitro. J Pineal Res. 2003;35:204–11.PubMed
101.
Girgert R, Bartsch C, Hill SM, Kreienberg R, Hauf V. Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach. Neuroendocrinol Lett. 2003;24:440–4.PubMed
102.
Cos J, Fernandez R, Guezmes A, Sanchez-Barcelo EJ. Influcence of melatonin on invasive and metastic properties of MCF-7 human breast cancer cells. Cancer Res. 1998;58:4383–90.PubMed
103.
Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res. 2010;48:9–19.PubMedPubMedCentral
104.
Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res. 2012;52:282–90.PubMed
105.
Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res. 2013;54:373–80.PubMed
106.
Grin W, Grünberger WA. Significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Investig. 1998;45:62–5.
107.
Benitez-King G, Soto-Vega E, Ramirez-Rodriguez G. Melatonin modulates microfilament phenotypes in epithelial cells: implications for adhesion and inhibition of cancer cell migration. Histol Histopathol. 2009;24:789–99.PubMed
108.
Alonso-González C, González A, Martínez-Campa C, Gómez-Arozamena J, Cos S. Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. J Pineal Res. 2015;58:189–97.PubMed
109.
Alonso-González C, González A, Martínez-Campa C, Menendez-Menendez J, Gomez-Arozamena J, Garcia-Vidal A, Cos S. Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis. Cancer Lett. 2016;370:145–52.PubMed
110.
Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology. 2006;17:108–11.PubMed
111.
Menéndez-Menéndez J, Martínez-Campa C. Melatonin: an anti-tumor agent in hormone-dependent cancers, review article. Int J Endocrinol. 2018:3271948.
112.
Cohen M, Lippman M, Chabner B. Pineal gland and breast cancer. Lancet. 1978;312:P1381–2.
113.
Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Nat Cancer Inst. 2001;93:1563–8.PubMed
114.
Tamarkin L, Danforth D, Lichter A, Cohen M, Chabner B, Lippman M. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science. 1982;216:1003–5.PubMed
115.
Bartsch C, Bartsch H, Karasek M. Melatonin in clinical oncology. Neuroendocrinol Lett. 2002;23:30–8.PubMed
116.
Molis TM, Spriggs LL, Hill SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 1994;8:1681–90.PubMed
117.
Nowfar S, Treplitzky SR, Melancon K, Kiefer TL, Chieng Q, Dwivedi PD, Bischoff ED, Moroz K, Anderson MB, Dai J, Lai N, Yuan L, Hill SM. Tumor prevention by 9-cis-retinioic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. Breast Cancer Res Treat. 2002;72:33–43.PubMed
118.
Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Estrogen signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 2006;30:118–28.PubMed
119.
Kubatka P, Zubor P, Busselberg D, Kwon TK, Adamek M, Petrovic D, Opatrilova R, Gazdikova K, Caprnda M, Rodrigo L, Danko J, Kruzliak P. Melatonin and breast cancer: evidences from preclinical and human studies. Crit Rev Oncology/Hematol. 2018;122:133–43.
120.
Cos S, Alvarez-García V, González A, Alonso-González C, Martínez-Campa C. Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (review). Oncol Lett. 2014;8:487–92.PubMedPubMedCentral
121.
James P, Bertrand KA, Hart JE, Schernhammer ES, Tamimi RM, Laden F. Outdoor light at night and breast cancer incidence in the nurses’ health study II. Env Health Perspectives. 2017;125:087010.
122.
Garcia-Saenz A, Sánchez de Miguel A, Espinosa A, Valentin A, Aragonés N, Llorca J, Amiano P, Sánchez VM, Guevara M, Capelo R, Tardon A, Peiró-Perez R, Jiménez-Moleón JJ, Roca-Barceló A, Pérez-Gómez B, Dierssen-Sotos T, Fernández-Villa T, Moreno-Iribas C, Moreno V, García-Pérez J, Castaño-Vinyals G, Pollán M, Aubé M, Kogevinas M. Evaluating the association between artificial light-at-night exposure and breast and prostate cancer risk in Spain (MCC-Spain study). Env Health Perspectives. 2018;126:047011.
123.
Stevens RG, Rea MS. Light in a built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control. 2001;12:279–87.PubMed
124.
Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology. 2001;12:74–7.PubMed
125.
Coleman MP, Reiter RJ. Breast cancer, blindness and melatonin. Eur J Cancer Clin Oncol. 1992;28:501–3.
126.
Xiang S, Dauchy RT, Hauch A, Mao L, Yuan L, Wren MA, Belancio VP, Mondal D, Frasch P, Blask DE, Hill SM. Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. J Pineal Res. 2015;59:60–9.PubMedPubMedCentral
127.
Regelson W, Pierpaoli MD. Melatonin: A rediscovered antitumor hormone? Its relation to surface receptors sex steroid metabolism, immunologic response, and chronobiologic factors in tumor growth and therapy. Cancer Investig. 1987;5:379–85.
128.
Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005;39:360–6.PubMed
129.
Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clinical Practice. 2007;61:835–45.
130.
Pawlikowsky M, Winczyk K, Karasek M. Oncostatic action of melatonin: facts and question marks. Neuroendocrinol Lett. 2002;23:24–9.
131.
Chao YH, Wu KH, Yeh CM, Su SC, Reiter RJ, Yang SF. The potential utility of melatonin in the treatment of childhood cancer. J Cell Physiol. 2019;234:19158–66.PubMed
132.
Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res. 2011;50:374–80.PubMed
133.
Najafi M, Shayesteh MRH, Mortezaee K, Farhood B, Haghi-Aminjan H. The role of melatonin on doxorubicin-induced cardiotoxicity: a systematic review. Life Sci. 2020;241:117173.PubMed
134.
Imenshahidi M, Karimi G, Hosseinzadeh H. Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review. Naunyn Schmiedebergs Archives Pharmacol. 2020;393:521–36.
135.
Zarezadeh M, Khorshidi M, Emami M, Janmohammadi P, Kord-varkaneh H. Mousavi SM, Mohammed SH, Saedisomeolia A, Alizadeh S. Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials. Eur J Nutr 2019; https://​doi.​org/​10.​1007/​s00394-019-02123-0, 59, 1803, 1813.
136.
Jang SS, Kim WD, Park WY. Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells. J Pineal Res. 2009;47:147–55.PubMed
137.
Ishitobi M, Shiba M, Nakayama T, Motomura K, Koyama H, Nishiyama K, Tamaki Y. Treatment sequence of aromatase inhibitors and radiotherapy and long-term outcomes of breast cancer patients. Anticancer Res. 2014;34:4311–4.PubMed
138.
Jawed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES, Niles LP. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol. 2007;560:17–22.PubMed
139.
Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Manton KG, Semenchenko AV, Yashin AI. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer. 2003;103:300–5.PubMed
140.
141.
Ma C, Li LX, Zhang Y, Xiang C, Ma T, Ma ZQ, Zhang ZP. Protective and sensitive effects of melatonin combined with Adriamycin on ER+ (estrogen receptor) breast cancer. Eur J Gynaecol Oncol. 2016;36:197–202.
142.
Kosar PA, Naziroglu M, Ovey IS, Cig B. Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: involvement of TRPV1 channels. J Membrane Biol. 2016;249:129–40.
143.
Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, Maestroni G. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. J Pineal Res. 1997;5:126–9.
144.
Dubbels R, Reiter RJ, Goebel A, Schnakenberg GE, Ehlers C, Schiwara HW, Schloot W. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry. J Pineal Res. 1995;18:28–31.
145.
Ferrua B, Masseyeff R. Immunoassay of melatonin with enzyme-labeled antibodies. J Immunoass. 1985;6:79–94.
146.
Honma A, Revell VL, Gunn PJ, Davies SK, Middleton B, Raynaud FI, Skene DJ. Effect of acute total sleep deprivation on plasma melatonin, cortisol and metabolite rhythms in females. Eur J Neurosci. 2020;51:366–78.PubMed
147.
Sengupta A, Weljie AM. Metabolism of sleep and aging: bridging the gap using metabolomics. Nutr Health Aging. 2019;5:167–84.
148.
149.
Mills MH, Finlay DC, Haddad PR. Determination of melatonin and mono-amines in rat pineal using reversed-phase ion-interaction chromatography with fluorescence detection. J Chromatogr A. 1991;564:93–102.
150.
Peniston-Bird JF, Di WL, Street CA, Kadva A, Stalteri MA, Silman SE. HPLC assay of melatonin in plasma with fluorescence detection. Clin Chem. 1993;39:2242–7.PubMed
151.
Chin JR. Determination of six indolic compounds, including melatonin, in rat pineal using high-performance liquid chromatography with serial fluorimetric-electrochemical detection. J Chromatogr. 1990;528:111–21.PubMed
152.
Vieira R, Míguez J, Lerna M, Aldegunde M. Pineal and plasma melatonin a determined by high-performance liquid chromatography with electrochemical detection. Anal Biochem. 1992;205:300–5.PubMed
153.
Skene DJ, Leone RM, Young IM, Silman RE. The assessment of a plasma melatonin assay using gas chromatography negative ion chemical ionization mass spectrometry. Biomed Mass Spectrom. 1983;10:655–9.PubMed
154.
Fourtillan JB, Gobin P, Faye B, Girault J. A highly sensitive assay of melatonin at the femotogram level in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom. 1994;23:499–509.PubMed
155.
Simonin G, Bru L, Lelièvre E, Jeanniot J-P, Bromet N, Walther B, Boursier-Neyret C. Determination of melatonin in biological fluids in the presence of the melatonin agonist S 20098: comparison of immunological techniques and GC-MS methods. J Pharm Biomed Anal. 1999;21:591–601.PubMed
156.
Yang S, Zheng X, Xu Y, Zhou X. Rapid determination of serum melatonin by ESI–MS–MS with direct sample injection. J Pharm Biomed Anal. 2002;30:781–90.PubMed
157.
Jensen MA, Hansen AM, Abrahamsson P, Norgaard AW. Development and evaluation of a liquid chromatography tandem mass spectrometry method for simultaneous determination of salivary melatonin, cortisol and testosterone. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:2527–32.PubMed
158.
Carter MD, Calcutt MW, Malow BA, Rose KL, Hachey DL. Quantitation of melatonin and N-acetylserotonin in human plasma by nanoflow LC-MS/MS and electrospray LC-MS/MS. J Mass Spectrom. 2012;47:277–85.PubMedPubMedCentral
159.
Khan SA, George R, Charles BG, Taylor P, Heussler HS, Couper DM, McGuire TM, Pache D, Norris D. Monitoring salivary melatonin concentrations in children with sleep disorders using liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2013;35:388–95.PubMed
160.
Wang H, Walaszczyk EJ, Li K, Chung-Davidson Y-W, Li W. High-performance liquid chromatography with fluorescence detection and ultra-performance liquid chromatography with electrospray tandem mass spectrometry method for the determination of indoleamine neurotransmitters and their metabolites in sea lamprey plasma. Anal Chim Acta. 2012;721:147–53.PubMed
161.
Hadrevi J, Jonsdottir IH, Jansson P-A, Eriksson JW, Sjörs A. Plasma metabolomic patterns in patients with exhaustion disorder. Stress. 2019;22:17–26.PubMed
162.
163.
Härtter S, Morita S, Bodin K, Ursing C, Tybring C, Bertilsson L. Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography–mass spectrometry. Ther Drug Monit. 2001;23:282–6.PubMed
164.
Xu J, Huang L. Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis. Sci Rep. 2017;7:5353–63.PubMedPubMedCentral
Metadata
Title
Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases
Authors
Andreea Iulia Socaciu
Răzvan Ionuţ
Mihai Adrian Socaciu
Andreea Petra Ungur
Maria Bârsan
Angelica Chiorean
Carmen Socaciu
Armand Gabriel Râjnoveanu
Publication date
01-12-2020
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2020
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09570-9

Other articles of this Issue 4/2020

Reviews in Endocrine and Metabolic Disorders 4/2020 Go to the issue

Correction

Correction to: Diet approach before and after bariatric surgery

ReviewPaper

Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm

ReviewPaper

Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management

ReviewPaper

Acromegaly, inflammation and cardiovascular disease: a review

ReviewPaper

Clinical features, diagnosis and treatment of Paget’s disease of bone in mainland China: A systematic review

ReviewPaper

Current perspectives of oleic acid: Regulation of molecular pathways in mitochondrial and endothelial functioning against insulin resistance and diabetes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits